# A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

> **NCT02407236** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 961 (actual)

## Conditions studied

- Colitis, Ulcerative
- Inflammatory Bowel Diseases

## Interventions

- **DRUG:** Placebo IV
- **DRUG:** Placebo SC
- **DRUG:** Ustekinumab IV
- **DRUG:** Ustekinumab SC

## Key facts

- **NCT ID:** NCT02407236
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-10
- **Primary completion:** 2018-08-10
- **Final completion:** 2021-11-30
- **Target enrollment:** 961 (ACTUAL)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02407236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02407236, "A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02407236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*